1. Adams JS, Hewison M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008; 4: 80–90.
2. Anderson JL, May HT, Horne BD et al. Intermountain Heart Collaborative (IHC) Study Group. Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 2010; 106: 963–968.
3. Bischoff-Ferrari HA, Borchers M, Gudat F et al. Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 2004; 19: 265–269.
4. Brewer LC, Michos ED, Reis JP. Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets 2011; 12: 54–60.
5. Buell JS, Dawson-Hughes B, Scott TM et al. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology 2010; 74: 18–26.
6. Buell JS, Scott TM, Dawson-Hughes B et al. Vitamin D is associated with cognitive function in elders receiving home health services. J Gerontol A Biol Sci Med Sci 2009; 64: 888–895.
7. Carda S, Cisari C, Invernizzi M et al. Osteoporosis after stroke: a review of the causes and potential treatments. Cerebrovasc Dis 2009; 28: 191–200.
8. Cooper R, Rotimi C. Hypertension in populations of West African origin: is there a genetic predisposition? J Hypertens 1994; 12: 215–227.
9. Corrado E, Rizzo M, Coppola G et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb 2010; 17: 1–11.
10. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 2009; 132: 1146–1160.
11. Faridi MM, Aggarwal A. Phenytoin induced vitamin D deficiency presenting as proximal muscle weakness. Indian Pediatr 2010; 47: 624–625.
12. Gouni-Berthold I, Krone W, Berthold HK. Vitamin D and Cardiovascular Disease. Curr Vasc Pharmacol 2009; 7: 414–422.
13. Handunnetthi L, Ramagopalan SV, Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology 2010; 74: 1905–1910.
14. Hayes CE, Nashold FE, Spach KM et al. The immunological functions of the vitamin D endocrine system. Cell Mol Biol 2003; 49: 277–300.
15. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266–281.
16. Kendrick J, Targher G, Smits G et al. 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. Atherosclerosis 2009; 205: 255–260.
17. Kunes J, Tremblay J, Bellavance F et al. Influence of environmental temperature on the blood pressure of hypertensive patients in Montreal. Am J Hypertens 1991; 4: 422–426.
18. Kurtzke JF. Geography in multiple sclerosis. J Neurol 1977; 215: 1–26.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444–1452.
20. Lee JH, O’Keefe JH, Bell D et al. Vitamin D deficiency: an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949–1956.
21. Libby P, Okamoto Y, Rocha VZ et al. Inflammation in atherosclerosis: transition from theory to practice. Circ J 2010; 74: 213–220.
22. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 2002; 8: 174–179.
23. Mehta B, Ramanathan M, Weinstock-Guttman B. Vitamin D and multiple sclerosis: can vitamin D prevent disease progression? Expert Rev Neurother 2011; 11: 469–471.
24. Munger KL, Levin LI, Hollis BW et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.
25. Nadir MA, Szwejkowski BR, Witham MD. Vitamin D and cardiovascular prevention. Cardiovasc Ther 2010; 28: e5–e12.
26. Norman AW. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006; 147: 5542–5548.
27. O’Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90: 18L–21L.
28. Oudshoorn C, Mattace-Raso FU, van der Velde N et al. Higher serum vitamin D3 levels are associated with better cognitive test performance in patients with Alzheimer’s disease. Dement Geriatr Cogn Disord 2008; 25: 539–543.
29. Peechakara SV, Pittas AG. Vitamin D as a potential modifier of diabetes risk. Nat Clin Pract Endocrinol Metab 2008; 4: 182–183.
30. Pittas AG, Dawson-Hughes B, Li T et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29: 650–656.
31. Pittas AG, Lau J, Hu FB et al. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab 2007; 92: 2017–2029.
32. Poole KE, Loveridge N, Barker PJ et al. Reduced vitamin D in acute stroke. Stroke 2006; 37: 243–245.
33. Przybelski RJ, Binkley NC. Is vitamin D important for preserving cognition? A positive correlation of serum 25-hydroxyvitamin D concentration with cognitive function. Arch Biochem Biophys 2007; 460: 202–205.
34. Reis JP, von Mühlen D, Michos ED et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis 2009; 207: 585–590.
35. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1997; 30: 150–156.
36. Schleithoff SS, Zittermann A, Tenderich G et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 2006; 83: 754–759.
37. Smolders J, Damoiseaux J, Menheere P et al. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol 2008; 194: 7–17.
38. Smolders J, Menheere P, Kessels A et al. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 2008; 14: 1220–1224.
39. Smolders J, Thewissen M, Peelen E et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009; 4: e6635.
40. Smolders J. Vitamin d and multiple sclerosis: correlation, causality, and controversy. Autoimmune Dis 2010; 2011: 629538.
41. Targher G, Bertolini L, Padovani R et al. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf) 2006; 65: 593–597.
42. The European Stroke Organisation (ESO): ESO Guidelines for Management of Ischaemic Stroke 2009.
43. van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005; 97: 93–101.
44. van der Mei IA, Ponsonby AL, Dwyer T et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003; 327: 316.
45. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999; 69: 842–856.
46. Wallis DE, Penckofer S, Sizemore GW. The “sunshine deficit” and cardiovascular disease. Circulation 2008; 118: 1476–1485.
47. Wilkins CH, Sheline YI, Roe CM et al. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 2006; 14: 1033–1040.
48. Woodhouse PR, Khaw KT, Plummer M. Seasonal variation of blood pressure and its relationship to ambient temperature in an elderly population. J Hypertens 1993; 11: 1267–1274.
49. Wüthrich R, Rieder HP. The seasonal incidence of multiple sclerosis in Switzerland. Eur Neurol 1970; 3: 257–264.
50. Yildiz M, Tettenborn B, Putzki N. Vitamin D levels in Swiss multiple sclerosis patients. Swiss Med Wkly 2011; 141: w13192.